Inaktiver Wert

Andere Sprachen Clarmin Explorations Inc. Toronto S.E.

Aktien

A2QJAV

CA23256X1006

CYBN

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase	14.05.
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones	07.05.
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones	06.05.
Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	06.05.
Cybin to Participate at the 27th Annual Milken Institute Global Conference	25.04.
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry	18.04.
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	17.04.
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	16.04.
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder	16.04.
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	10.04.
Cybin : MATERIAL CHANGE REPORT - Form 6-K	22.03.
Cybin : AGENCY AGREEMENT - Form 6-K	21.03.
Cybin Inc. announced that it has received $150 million in funding from a group of investors	19.03.
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas	18.03.
Sector Update: Health Care Stocks Softer Friday Afternoon	15.03.
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder	15.03.
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder	15.03.
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder	15.03.
Discovering Promising Tech Stocks: QBTS, GEVI, CYBN, RSCI, CLRO	15.03.
Cybin annonce une réunion positive avec la FDA à la fin de la phase 2 pour le CYB003 dans le trouble dépressif majeur et la conception du programme de phase 3	14.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Clarmin Explorations Inc. Toronto S.E.

Aktien

A2QJAV

CA23256X1006

CYBN

Andere Sprachen

Filter